Trials / Active Not Recruiting
Active Not RecruitingNCT05165264
A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer
A National, Prospective, Non-interventional Study (NIS) of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Patients With HER2 Negative Advanced or Metastatic Gastric, Gastro-oesophageal Junction or Oesophageal Adenocarcinoma Whose Tumours Express PD-L1 With a CPS ≥5
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to assess the effectiveness and safety of nivolumab in participants with previously untreated advanced or metastatic Gastric Cancer (GC), Gastro-oesophageal Junction (GEJ) Adenocarcinoma, or Oesophageal Adenocarcinoma (EAC).
Conditions
Timeline
- Start date
- 2022-02-16
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2021-12-21
- Last updated
- 2025-03-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05165264. Inclusion in this directory is not an endorsement.